Compare HTZ & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | GHRS |
|---|---|---|
| Founded | 1918 | 2018 |
| Country | United States | Ireland |
| Employees | 26000 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | HTZ | GHRS |
|---|---|---|
| Price | $4.75 | $14.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.93 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 5.2M | 203.0K |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $7.98 |
| 52 Week High | $9.39 | $19.51 |
| Indicator | HTZ | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 44.44 |
| Support Level | $3.78 | $13.75 |
| Resistance Level | $5.47 | $14.80 |
| Average True Range (ATR) | 0.26 | 0.85 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 72.79 | 38.14 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.